An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
Ghobrial
Irene M
IM
Otteman
Larry A
LA
White
William L
WL
D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D015458:Leukemia, T-Cell / Q000188:drug therapy; D018655:Lymphocyte Count; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000821:virology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab